pharmaphorum
JANUARY 11, 2023
Over the past few decades, data generation has veritably exploded. However, the ‘Big Data paradigm’ is not so much concerned with the volume of that data, but how businesses and, indeed, industries can derive meaningful insights from what has become a glut of information. From Big Data to small.
Roots Analysis
JANUARY 28, 2024
Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. It accounts for the majority of big data in healthcare and comprises information, such as medical images, surveys, chats, and written narratives.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 1, 2022
NLRP3 belongs to a family of proteins called inflammasome receptors. The latest development comes after Novo Nordisk entered a new strategic collaboration with Microsoft to speed up the discovery and development of drugs using big data and artificial intelligence.
pharmaphorum
DECEMBER 8, 2022
These groundbreaking discoveries ushered in a new age of precision and personalized medicine, leading to innovations in novel targeted proteins, cell and gene therapies, and medical devices, which are often accompanied by bespoke diagnostic and testing criteria.
pharmaphorum
SEPTEMBER 16, 2022
A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Kim recognised then, he said, that better tools for medicine needed to be developed, and that they still do.
Delveinsight
AUGUST 18, 2021
Smartphone applications provide information related to nutritional status in recipes by segmenting them into fats, proteins, carbohydrates, and sugars. Apart from these, the entry of big data and Virtual health technologies will also provide new insights and support to Diabetes management immensely in the coming years.
pharmaphorum
SEPTEMBER 18, 2020
The same year, AZ also entered into its third collaboration agreement with Astex Therapeutics, this time to develop small-molecule protein kinase B (PKB) to further contribute in the fight against cancer. AstraZeneca’s first acquisition following its creation was of KuDOS Pharmaceuticals, a UK biotech company, for £120 million in 2005.
Expert insights. Personalized for you.
122 
Let's personalize your content